Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2012 2
2013 6
2014 16
2015 17
2016 14
2017 20
2018 13
2019 17
2020 8
2021 6
2022 11
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24562070

118 results

Results by year

Filters applied: . Clear all
Page 1
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ. Carrasquillo JA, et al. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8. Eur J Nucl Med Mol Imaging. 2013. PMID: 23653243 Free PMC article. Clinical Trial.
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H. Matsubara N, et al. Int J Clin Oncol. 2018 Feb;23(1):173-180. doi: 10.1007/s10147-017-1176-0. Epub 2017 Aug 2. Int J Clin Oncol. 2018. PMID: 28770408 Free PMC article. Clinical Trial.
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, Trandafir L, Wagner V, Li R, Nordquist LT. Sartor O, et al. Prostate. 2019 Oct;79(14):1683-1691. doi: 10.1002/pros.23893. Epub 2019 Aug 23. Prostate. 2019. PMID: 31442327 Free PMC article. Clinical Trial.
Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K, Miyoshi Y, Shindo T, Hori M, Tsuboi Y, Kobayashi K, Fukuta F, Tanaka T, Miyamoto S, Maehana T, Okada M, Nishiyama N, Yanase M, Kato R, Hotta H, Kunishima Y, Takahashi A, Hinotsu S, Sakata KI, Kitamura H, Uemura H, Masumori N. Hashimoto K, et al. Cancer Med. 2020 Nov;9(22):8579-8588. doi: 10.1002/cam4.3459. Epub 2020 Sep 22. Cancer Med. 2020. PMID: 32964674 Free PMC article.
118 results